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Abstract
The term pulmonary–renal syndrome refers to the combination of
diffuse alveolar haemorrhage and rapidly progressive glomerulo-
nephritis. A variety of mechanisms such as those involving anti-
glomerular basement membrane antibodies, antineutrophil cyto-
plasm antibodies or immunocomplexes and thrombotic microangio-
pathy are implicated in the pathogenesis of this syndrome. The
underlying pulmonary pathology is small-vessel vasculitis involving
arterioles, venules and, frequently, alveolar capillaries. The under-
lying renal pathology is a form of focal proliferative glomerulo-
nephritis. Immunofluorescence helps to distinguish between anti-
glomerular basement membrane disease (linear deposition of IgG),
lupus and postinfectious glomerulonephritis (granular deposition of
immunoglobulin and complement) and necrotizing vasculitis (pauci-
immune glomerulonephritis). Patients may present with severe
respiratory and/or renal failure and require admission to the
intensive care unit. Since the syndrome is characterized by a
fulminant course if left untreated, early diagnosis, exclusion of
infection, close monitoring of the patient and timely initiation of
treatment are crucial for the patient’s outcome. Treatment consists
of corticosteroids in high doses, and cytotoxic agents coupled with
plasma exchange in certain cases. Renal transplantation is the only
alternative in end-stage renal disease. Newer immunomodulatory
agents such as those causing TNF blockade, B-cell depletion and
mycophenolate mofetil could be used in patients with refractory
disease.
Introduction
Pulmonary–renal syndrome is defined as the combination of
diffuse alveolar haemorrhage (DAH) and glomerulonephritis
[1-3]. Several types of immunologic injury as well as other
nonimmunologic mechanisms such as antiglomerular
basement membrane (anti-GBM) antibodies, antineutrophil
cytoplasm antibodies (ANCA), immunocomplexes and
thrombotic microangiopathy are involved in the syndrome’s
pathogenesis [4-8] (Table 1).
A significant number of patients will present with rapid clinical
deterioration and require admission to the intensive care unit
(ICU) [9-12]. This is attributed either to exacerbation of the
disease activity itself, or to infectious complications
secondary to severe immunosuppressive treatment [10,12].
Pulmonary–renal syndromes represent a major challenge in
the ICU since the outcome is based on early and accurate
diagnosis and aggressive treatment [13]. Nevertheless,
mortality can reach 25–50% [14].
The aim of the present article is to provide the intensivist with
an overview of pulmonary–renal syndrome, focusing on new
concepts of its pathogenesis and treatment innovations.
Pathology of pulmonary–renal syndrome
The underlying pulmonary lesion in the majority of cases of
pulmonary–renal syndrome is small-vessel vasculitis, charac-
terized by a destructive inflammatory process that involves
arterioles, venules and alveolar capillaries (necrotic pulmonary
capillaritis). These lesions disrupt perfusion and the continuity
of the pulmonary capillary wall, allowing blood to extravasate
in the alveolar space. This is clinically expressed with DAH
[15].
The underlying renal pathology in the majority of cases of
pulmonary–renal syndrome is a form of focal proliferative
glomerulonephritis [16]. Fibrinoid necrosis is frequently seen,
as well as microvascular thrombi. Extensive crescent forma-
tion regularly accompanies glomerular tuft disease. Interstitial
infiltration, fibrosis and tubular atrophy are poor prognostic
factors. Necrotizing granulomas and small-vessel vasculitis
are rare findings. Immunofluorescence helps to distinguish
among anti-GBM disease (linear deposition of IgG), lupus
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and postinfectious glomerulonephritis (granular deposition of
immunoglobulin and complement), and necrotizing vasculitis
(pauci-immune glomerulonephritis) [17,18].
Epidemiology and pathogenesis of
pulmonary–renal syndrome
Pulmonary–renal syndrome associated with anti-GBM
antibodies: Goodpasture’s syndrome
The term ‘Goodpasture’s syndrome’ is used for the clinical
entity of DAH and rapidly progressive glomerulonephritis
associated with anti-GBM antibodies [19,20].
Goodpasture’s syndrome is extremely rare (one case per
1,000,000 population per year). The disease predominantly
affects Caucasians of every age but mostly those in the
second to third decades and the fifth to sixth decades of life,
with a slight predominance of males. Although rare, this
syndrome is responsible for about 20% of acute renal failure
cases due to rapidly progressive glomerulonephritis [19].
Both genetic and environmental factors have been implicated
in the pathogenesis of Goodpasture’s syndrome. The disease
has been described in brothers and in identical twins. More
than 80% of patients carry the HLA alleles DR15 or DR4
whereas the alleles DR7 and DR1 are rarely found,
suggesting that the latter may play a protective role [21]. The
fact that most cases present sporadically implies an
additional aetiology beyond hereditary predisposition.
Environmental factors, such as smoking, infections and
previous hydrocarbon exposure, have been implicated in
triggering the disease [22].
Table 1
Pulmonary–renal syndromes
Clinical entities classified according to the pathogenetic mechanism involved
Pulmonary–renal syndrome associated with anti-GBM antibodies: Goodpasture’s syndrome
Pulmonary–renal syndrome in ANCA-positive systemic vasculitis
Wegener’s granulomatosis
Microscopic polyangiitis
Churg–Strauss syndrome
Other vasculitis
Pulmonary–renal syndrome in ANCA-negative systemic vasculitis 
Henoch–Schönlein purpura 
Mixed cryoglobulinaemia
Behçet’s disease 
IgA nephropathy
ANCA-positive pulmonary–renal syndrome without systemic vasculitis: idiopathic pulmonary–renal syndrome
Pauci-immune necrotic glomerulonephritis and pulmonary capillaritis
Pulmonary–renal syndrome in drug-associated ANCA-positive vasculitis
Propylthiouracil
D-Penicillamine
Hydralazine
Allopurinol
Sulfasalazine
Pulmonary–renal syndrome in anti-GBM-postive and ANCA-positive patients
Pulmonary–renal syndrome in autoimmune rheumatic diseases (immune complexes and/or ANCA mediated)
Systemic lupus erythematosus
Scleroderma (ANCA?)
Polymyositis
Rheumatoid arthritis
Mixed collagen vascular disease
Pulmonary–renal syndrome in thrombotic microangiopathy
Antiphospholipid syndrome
Thrombotic thrombocytopenic purpura 
Infections
Neoplasms
Diffuse alveolar haemorrhage complicating idiopathic pauci-immune glomerulonephritis
anti-GBM, antiglomerular basement membrane; ANCA, antineutrophil cytoplasm antibodies.Page 3 of 11
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Human anti-GBM antibodies belong mostly to the IgG class
and react with a limited number of epitopes (EA and EB) on
the noncollageneous domain of the α3 chain of type IV
collagen (NC1 α3 IV), a molecule expressed in the basement
membranes of renal glomerulus, renal tubule, alveoli, chorioid
plexus, retinal capillaries and Bruchs’s membrane [16,20].
Anti-GBM antibodies bind the glomerular basement
membrane, activating compliment and proteases, resulting in
the disruption of the filtration barrier and Bowman’s capsule
and causing proteinuria and crescent formation [23,24]. The
pathogenetic role of anti-GBM has been proved in multiple
studies [20]. As an example, in genetically engineered mice
that produce human IgG antibodies, immunization with the
NC1 α3 IV domains leads to the production of human anti-
GBM antibodies and proliferative glomerulonephritis [25].
Pulmonary–renal syndrome in ANCA-positive systemic
vasculitis
Circulating ANCA autoantibodies are detected in the majority
of patients presenting with pulmonary–renal syndrome
[26,27]. ANCA do not confirm a specific entity but practically
lead the differential diagnosis to three major systemic
vasculitides syndromes: Wegener’s granulomatosis, micro-
scopic polyangiitis and Churg–Strauss syndrome [26].
Wegener’s disease or Wegener’s granulomatosis is charac-
terized by the triad of systemic necrotizing vasculitis,
necrotizing granulomatous inflammation of the upper and
lower respiratory tract, and necrotizing glomerulonephritis
[28]. The incidence of the disease is estimated up to
8.5/million (range 5.2–12.9/million) with a male-to-female ratio
of 1:1. The disease usually involves Caucasians (80–97%)
with a mean age at the time of diagnosis of 40–55 years,
although persons of every age may be affected [29]. The
lungs are involved in 90% of cases. In a small percentage of
patients, a limited form of the disease that spares the kidney
has been described [29,30].
Microscopic polyangiitis is a systemic small-vessel vasculitis
manifested by pauci-immune necrotic glomerulonephritis
(80–100% of patients), pulmonary capillaritis (10–30%), skin
lesions and arthralgias [31].
Churg–Strauss syndrome is a systemic disease, typically
presenting with an initial asthma/sinusitis phase, followed by
eosinophilia and vasculitis [9]. In Churg–Strauss syndrome,
renal involvement is milder compared with Wegener’s
disease, Goodpasture’s syndrome and microscopic poly-
angitis [32].
ANCA include three categories of antibodies based on their
pattern of indirect immunofluorescence on ethanol-fixed
neutrophils: a diffuse cytoplasmic granular pattern, a peri-
nuclear pattern, and an atypical pattern [33-35]. The
antigenic target for cytoplasmic ANCA is proteinase 3 (Pr3),
and that for perinuclear ANCA is myeloperoxidase (MPO).
ANCA are detected both through indirect immunofluores-
cence and ELISA [36,37].
Several lines of evidence suggest that ANCA are involved in
the pathogenesis of ANCA-associated diseases. Xiao and
colleagues demonstrated that anti-MPO IgG administration in
mice causes focal necrotizing and crescentic glomerulo-
nephritis [38]. In humans, a newborn developed glomerulo-
nephritis and pulmonary haemorrhage after intrauterine
transplacental transfer of ANCA IgG against MPO [39,40].
On the other hand, administration of anti-Pr3 antibodies in
mice alone does not induce glomerulonephritis. This adminis-
tration does, however, aggravate TNF-α-elicited inflammation,
suggesting that Pr3 ANCA have a proinflammatory activity in
conjunction with a primary inflammatory stimulus [41]. In
addition, ANCA were shown to enhance interactions
between leukocytes and endothelial cells and to cause micro-
vascular haemorrhage [42,43]. More precisely, the majority of
target antigens of ANCA such as Pr3 and MPO are
proteolytic enzymes of the azurophilic granules of neutrophils
[44]. Fixation of ANCA with Pr3 on the endothelial surface
induces expression of adhesion molecules and release of IL-8
that causes recruitment and attachment of neutrophils on the
endothelial cell surface, leading to vessel wall inflammation,
obliteration and damage [45].
Pulmonary–renal syndrome in ANCA-negative systemic
vasculitis
Pulmonary–renal syndrome in ANCA-negative systemic
vasculitis is very rare and has been described only occasionally
in Behçet’s disease, in Henoch–Schönlein purpura, in IgA
nephropathy and in mixed cryoglobulinaemia [46]. In
Henoch–Schönlein purpura, acute capillaritis and DAH
involve deposition of IgA immuno-complexes along the
pulmonary alveoli [47].
ANCA-positive pulmonary–renal syndrome without
systemic vasculitis: idiopathic pulmonary–renal syndrome
This entity includes the patients presenting with DAH, rapidly
progressive glomerulonephritis and positive ANCA (either
Pr3 or MPO), but with no other manifestation of systemic
vasculitis. Fever, malaise, weight loss, myalgias and
arthralgias may coexist. Mortality during the first episode of
the syndrome exceeds 50%. It is argued that the syndrome
represents either a limited type of microscopic polyangiitis or
a variant of Wegener’s syndrome [5].
Pulmonary–renal syndrome in drug-associated
ANCA-positive vasculitis
Drugs provide one of the potentially reversible causes of
ANCA-positive vasculitis. Most frequently they cause
perinuclear ANCA/MPO ANCA vasculitis, although cyto-
plasmic ANCA/Pr3 ANCA vasculitis has also been described
[48]. The drugs most frequently implicated in the pathogenesis
of the syndrome are propylthiouracil and hydralazine. ANCA are
detected in 20% of patients receiving propylthiouracil, but only
Available online http://ccforum.com/content/11/3/213a minority of these patients develop clinical manifestations of
systemic vasculitis including pulmonary–renal syndrome [49].
D-Penicillamine, allopurinol and sulfasalazine have also been
associated with pulmonary–renal syndrome.
Discontinuation of the causative drug most frequently leads
to regression of the disease; however, some patients
continue to present positive ANCA or even recurrent disease,
requiring long-term immunosuppressive treatment. In general,
drug-induced disease has a more benign course than ANCA-
positive pulmonary–renal syndrome of other aetiology [50].
Drugs should therefore be considered a potential cause of
MPO vasculitis, particularly among patients with high titres of
these antibodies [48].
Pulmonary–renal syndrome in both anti-GBM-positive
and ANCA-positive patients
In patients with pulmonary–renal syndrome, anti-GBM anti-
bodies are occasionally detected simultaneously with ANCA,
most frequently MPO ANCA [51,52]. The significance of this
finding is unknown. No cross-reactivity between the targets of
ANCA and anti-GBM antibodies has been found. It has been
speculated that ANCA-associated damage of the glomerular
membrane uncovers ‘hidden antigen’ inducing the formation
of anti-GBM antibodies [53].
Pulmonary–renal syndrome in autoimmune rheumatic
diseases (immune complexes and/or ANCA mediated)
Pulmonary–renal syndrome has been reported more often in
systemic lupus erythematosus and systemic sclerosis, and
rarely in rheumatoid arthritis and mixed connective tissue
disease. DAH ± glomerulonephritis occurs in 2% of systemic
lupus erythematosus patients and rarely is the first
manifestation of the disease [54,55]. Immune complex
deposition is frequently detected in both the pulmonary and
renal vessels with mortality rates between 70% and 90%,
among the highest of all causes of pulmonary–renal
syndrome [54,55]. Pulmonary–renal syndrome is a rare but
potentially lethal complication of systemic sclerosis, and often
coexists with pulmonary fibrotic disease [56]. In this case,
renal failure is normotensive, in contrast to the hypertensive
nephropathy characterizing systemic sclerosis. ANCA, more
often the perinuclear ANCA or MPO ANCA, have been
detected in some systemic sclerosis patients [57].
Pulmonary–renal syndrome in thrombotic
microangiopathy
Pulmonary–renal syndrome has been described in the
context of diseases characterized by thrombotic microangio-
pathy, such as antiphospholipid syndrome (APS), thrombotic
thrombocytopenic purpura, malignancies and infections.
Antiphospholipid syndrome
The term APS was used initially to characterize patients
presenting with the combination of antiphospholipid anti-
bodies and hypercoagulation syndrome. The diagnosis of the
disease actually requires the criteria defined in the very
informative paper of Levine and colleagues [58]. Antiphos-
pholipid antibodies are heterogeneous, and they target
negatively charged phospholipids and serum phospholipid-
binding proteins. The antibodies are frequently associated
with thrombosis, foetal loss and other clinical manifestations
of APS, and are thought to play an important role in the
pathogenesis of the syndrome. Antiphospholipid antibodies
inhibit activated protein C, antithrombin III and fibrinolysis and
upregulate tissue factor activity, thus leading to a
procoagulant state [59].
Pulmonary–renal syndrome has been described in the
context of acute catastrophic APS, defined as the APS that
develops over days or weeks characterized by multiple
thromboses in small and large vessels of at least three
different organ systems [60]. The kidney is the organ most
commonly involved (78%), followed by the lungs (66%), the
central nervous system (56%), the heart (50%), and the skin
(50%). Acute catastrophic APS results in adult respiratory
distress syndrome and in renal failure, leading up to 25% of
patients to haemodialysis [60,61].
Thrombotic thrombocytopenic purpura
Pulmonary–renal syndrome has also been described in patients
with thrombotic thrombocytopenic purpura [62]. Thrombotic
thrombocytopenic purpura is an often-fatal multisystem disease
characterized by thrombocytopenia, microangiopathic
haemolytic anaemia and ischemic manifestations due to
aggregation of platelets in the arterial microcirculation [63].
Recent studies suggest that the insufficiency of a specific
plasma metalloprotease responsible for the degradation of
von Willebrand factor cleavage protein (ADAMTS-13) is
involved in the pathogenesis of many familial and idiopathic
cases [64]. In some patients, inhibitory anti-von Willebrand
factor cleavage protein antibodies have been detected in
serum. Pregnancy, disseminated neoplasms and chemo-
therapy are considered predisposing factors. The detection
of hyaline thrombi in arterioles, venules and capillaries without
evidence of vascular inflammation is diagnostic [65-67].
Diffuse alveolar haemorrhage complicating idiopathic
pauci-immune glomerulonephritis
The term ‘pauci-immune’ glomerulonephritis has mainly been
used to indicate that no immunoglobulins, immune complexes
or complement can be detected in renal biopsy, either by
immunofluorescence or by electronic microscopy. Rarely, the
course of patients with idiopathic pauci-immune glomerulo-
nephritis may be complicated by DAH [5,6].
Clinical manifestation of pulmonary–renal
syndrome and evaluation of the critically ill
patient
Patients with pulmonary–renal syndrome may require admis-
sion to the ICU either because of the disease itself or
Critical Care    Vol 11 No 3 Papiris et al.
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frequent diagnoses in patients with pulmonary–renal syndrome
admitted to the ICU are perinuclear ANCA vasculitis,
followed by cytoplasmic ANCA vasculitis, Goodpasture’s
syndrome, systemic lupus erythematosus and catastrophic
APS [68-71] (Table 2 and Figure 1). The diagnosis is already
known in the majority of those patients admitted to the ICU;
the main cause of admission in these patients is infection or
adverse drug effects, including severe infectious
complications related to the immunosuppressive treatment.
More than one-third of the patients treated in ICU settings,
however, present with serious renal impairment and adult
respiratory distress syndrome of unknown aetiology [70,72].
Establishing the diagnosis is a particularly difficult task in
patients presenting with pulmonary infiltrates and fever,
having no prior disease label and without haemoptysis – a
clinical scenario resembling ‘pneumonia’. Even though the
lack of large prospective trials does not permit strict
recommendations, we propose that the possibility of a
pulmonary–renal syndrome should be considered in those
patients with bilateral pulmonary infiltrates in the face of the
following: falling haemoglobin levels, renal failure
necessitating haemodialysis, sinusitis, mononeuritis multiplex,
polyarthalgia, severe asthma attack, pericarditis, cerebral
ischaemia, purpura or congestive heart failure [69,73].
Furthermore, the treating physician should always bear in
mind that pulmonary–renal syndrome at first presentation may
not only mimic pneumonia, but in certain cases could be
triggered by pneumonia. Treatment of all these patients
should therefore include broad antibiotic cover until further
workup is performed [74].
Haemoptysis is the most common clinical manifestation of
DAH [5,6]. However, 30–35% of patients may have DAH
without evidence of haemoptysis. Breathlessness, cough and
low-grade fever may also be present. In about 50% of cases
of DAH, patients suffer acute respiratory failure requiring
mechanical ventilation [6]. The most common renal
manifestation of pulmonary–renal syndrome is haematuria,
proteinuria and active urinary sediment. If left untreated,
patients can progress to end-stage renal failure, requiring
haemodialysis [17].
Chest roentgenograms and computerized tomography
scanning are used to depict DAH. The former may be normal
in up to 22% of cases [75]. Common findings include
coalescent alveolar infiltrates or consolidations with air
bronchogram, and rarely ground glass opacities. The
distribution of the infiltrates is mainly perihilar or predominates
in the middle and lower pulmonary fields. Complete
roentgenographic resolution usually takes 3–4 days (or
occasionally even 1 day) provided the haemorrhage has
ceased. A persistence of the interstitial pattern may be
related to underlying disease or may indicate the presence of
primary pulmonary haemosiderosis, a result of indolent
chronic or recurrent DAH [76,77]. The presence of a diffuse
alveolar pattern with Kerley A, B, C linear shadows denotes
other causes such as veno-occlusive disease of the lung,
mitral valve stenosis or cardiogenic pulmonary oedema [78].
Urinalysis reveals dysmorphic red cells of glomerular origin,
red-cell casts and other cellular and granular casts.
Proteinuria is always present, but rarely in the range of
nephrotic syndrome [17,18]. In the vast majority of patients,
bound urea nitrogen and creatinine levels are elevated,
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Table 2
Relative frequencies of conditions contributing to pulmonary–renal syndrome in the intensive care unit [68-71]
Pourrat et al.  Gallagher et al.  Cruz et al.  Bucciarrelli et al. 
(2000) [68] (2002) [70] (2003) [69] (2006) [71]
Number of patients 33a 14b 26c 220d
Perinuclear ANCA vasculitis – 5 11 –
Cytoplasmic ANCA vasculitis 2 5 5 –
Goodpasture’s syndrome 3 – 1 –
Antiglomerular basement membrane/perinuclear  – 2 – –
ANCA positive
Catastrophic antiphospholipid syndrome with adult  – – 56
respiratory distress syndrome
Other 28 2 10 164
aThirty-three patients admitted to the intensive care unit with ‘systemic disease’. ‘Other’ includes eight cases of systemic lupus erythematosus.
bFourteen patients with pulmonary–renal syndrome. ‘Other’ included one case of systemic lupus erythematosus. cTwenty-six patients with systemic
necrotizing vasculitis. ‘Perinuclear antineutrophil cytoplasm antibodies (ANCA) vasculitis’ included Churg–Strauss syndrome and microscopic
polyangiitis. ‘Other’ included polyarteritis nodosa, HIV-related vasculitis, cryoglobulinaemic vasculitis and Henoch–Schönlein purpura. dTwo
hundred and twenty patients with catastrophic antiphospholipid syndrome included in the catastrophic antiphospholipid syndrome registry. ‘Other’
included catastrophic antiphospholipid syndrome without adult respiratory distress syndrome.associated with oliguria, hypertension and oedema. A
normochromic normocytic anaemia is frequently observed
and is more profound than expected from the degree of renal
failure [16]. Laboratory findings of Coomb’s negative
haemolytic anaemia with schistocytes or fragmented red cells
on peripheral blood examination in combination with thrombo-
cytopenia and minimal activation of coagulation mechanisms
are suggestive of thrombotic thrombocytopenic purpura [63].
All necessary samples such as sputum and blood cultures, as
well as serology tests, should be obtained to rule out
bacterial infection or viral infection. When pulmonary–renal
syndrome is clinically suspected, the detection in serum of
antibodies such as anti-GBM and/or ANCA is of major
importance. The use of serology to direct therapeutic
decisions may be extremely complicated and should be
based on the performance characteristics of the test
(sensitivity and specificity) as well as on the pretest
probability of the disease. In this regard, ANCA testing can
be safely interpreted as ‘documentation of the diagnosis’ in
patients with strong clinical suspicion for pauci-immune
crescentic glomerulonephritis; on the contrary, in patients
with weak clinical evidence of the disease, a positive result
requires further testing while a negative result can be used to
exclude such a diagnosis [79].
Anti-GBM antibodies detected using different immunoassays
have a sensitivity of 95–100% and a specificity of 90–100%
for Goodpasture’s syndrome [80-82]. Cytoplasmic ANCA are
found in more than 85% of patients with generalized
Wegener’s granulomatosis and in 60% of patients with the
limited form of the disease [83]. Approximately 40–80% of
patients with microscopic polyangiitis have ANCA, mainly
perinuclear ANCA/MPO ANCA. Positive perinuclear ANCA/
MPO ANCA and a negative serological test for hepatitis B
are, in general, suggestive of microscopic polyangiitis [84].
Of the patients with Churg–Strauss syndrome, 35–70% have
positive perinuclear ANCA/MPO ANCA, while only 10% have
positive Pr3 ANCA [85,86].
According to the International Consensus Statement on
Testing and Reporting of antineutrophil cytoplasmic
antibodies, combining indirect immunofluorescence essays
and enzyme immunoassays (ELISAs) for Pr3 and MPO is
more accurate than either assay alone [87]. It is important to
note, however, that not all patients with ANCA-associated
vasculitis will test positive for ANCA, and therefore ANCA are
not considered a diagnostic criterion [88]. On the other hand,
ANCA have also been detected in several other autoimmune
nonvasculitic disorders, such as inflammatory bowel disease,
rheumatoid arthritis and autoimmune hepatitis as well as in
infectious and neoplastic diseases [89,90].
Bronchoscopy should be performed to rule out infection and
to evaluate the presence of DAH. Recovery of haemorrhagic
fluid on bronchoalveolar lavage, especially if the sample
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Figure 1
Relative frequencies of conditions contributing to pulmonary–renal syndrome in the intensive care unit. Relative frequencies of conditions
contributing to pulmonary–renal syndrome in the intensive care unit based on mean values from data on patients’ characteristics provided by
[69,70] (shown in detail in Table 2). Perinuclear antineutrophil cytoplasmic antibodies (P-ANCA) vasculitis is the most frequent cause of
pulmonary–renal syndrome for patients admitted to the intensive care unit. ‘Other’ includes systemic lupus erythematosus, catastrophic
antiphospholipid syndrome, polyarteritis nodosa, HIV-related vasculitis, cryoglobulinaemic vasculitis and Henoch–Schönlein purpura. C-ANCA,
cytoplasmic antineutrophil cytoplasmic antibodies; anti-GBM, antiglomerular basement membrane.becomes bloodier from the first to the last suctioned syringe,
and acute decrease of the haematocrit coupled with a chest
roentgenogram showing multiple coalescent alveolar
shadows strongly suggest the diagnosis of DAH [6].
The gold standard for diagnosis of pulmonary–renal
syndrome is pulmonary and/or renal biopsy. Percutaneous
renal biopsy is often performed and specimens undergo
conventional histopathology and immunofluorescence study
[91,92]. When the lung is involved, a surgical or a
thoracoscopic lung biopsy may be performed. Tissue should
always be processed for additional immunofluorescence and
microbiology studies [81].
In the case of Goodpasture’s syndrome, anti-GBM antibody
deposition on the glomerular and alveolar basement
membrane can be detected in renal and/or lung tissue by
immunofluorescence as a linear staining along the glomerular
and/or the alveolar basement membrane, respectively. In
Wegener’s granulomatosis, the three major pathologic
features on lung biopsy include granuloma, inflammation of
the vascular wall (arteriolar, venular or capillary) and areas of
geographic necrosis [83,91]. The histologic criteria of
Churg–Strauss syndrome include necrotizing vasculitis in
affected tissues, eosinophilic tissue infiltration and extra-
vascular granulomas [84].
Critically ill patients are unfortunately high-risk operative
candidates for lung or renal biopsy [93]. Although biopsies of
other organs (skin, sinus, nerves) can be used, appropriate
treatment should be promptly initiated even in the absence of
histopathological confirmation to minimize morbidity and
mortality in patients with high clinical suspicion of ANCA-
associated or anti GBM-associated vasculitis and with a
positive ANCA or anti-GBM antibodies result, respectively
[14,34]. When initial treatment is initiated (see below),
patients should be closely monitored for response to therapy.
Improvement of a chest X-ray, of arterial blood gases, of renal
function, of neurologic signs and of other signs (such as
purpura) is expected to start during the first few days of the
initiation of treatment in those patients responding to therapy.
Recovery is less common for patients on dialysis, but dialysis
can be discontinued in more than one-half of them. When
patients deteriorate, the differential diagnosis includes
refractory pulmonary–renal syndrome, drug-adverse effects,
infection with sepsis and another underlying disease. In these
cases, invasive diagnostic efforts should be performed
without further delay and empirical treatment should be
reevaluated with a highly expert team of physicians along with
the treating doctors [9,10].
Treatment of pulmonary–renal syndrome in
the critically ill patient
Therapy is subdivided into the induction-remission phase and
the maintenance phase [94,95]. In the following, treatment for
ANCA-associated vasculitides, for Goodpasture’s syndrome
and for pulmonary–renal syndrome of variant aetiology will be
discussed. It is uncommon that the intensivist treats patients
with pulmonary–renal syndrome in remission, unless drug
toxicity and infectious immunosuppressive treatment
complications ensue.
ANCA-associated pulmonary–renal syndrome
Immunosuppression is the cornerstone of treatment in ANCA-
associated pulmonary–renal syndrome. Standard induction-
remission regimens include pulse intravenous methyl-
prednisolone (500–1,000 mg) for 3–5 days. As the life-
threatening features subside, the dose can then be reduced
to 1 mg/kg prednisone (or equivalent) daily for the first month,
tapered over the next 3–4 months. Glucocorticoid therapy is
combined with cytotoxic agents. Cyclophosphamide is the
treatment of choice in critically ill patients with generalized
disease, at a dose of 0.5–1 g/m2 administered intravenously
as a pulse per month or orally (1–2 mg/kg/day) [87,88].
Severe disease defined by major renal impairment (serum
creatinine >5.7 mg/dl) was recently suggested to be treated
with corticosteroids and cyclophosphamide coupled with
plasma exchange at least for the first week to increase the
likelihood for renal function restoration [96,97]. There are
reports suggesting that extracorporeal membrane oxygena-
tion and activated human factor VII may be beneficial in some
critically ill patients with DAH [98-100].
With this treatment, approximately 85% of patients achieve
remission [94,95]. Transition to maintenance therapy may
occur 6–12 months after the initiation of induction therapy or
after clinical remission [101]. The maintenance therapy
includes low-dose corticosteroids coupled with cytotoxic
agents
Relapse will occur in 11–57% of patients in remission. Some
relapses are severe, resulting in end-organ damage. Female
or black patients and those patients with severe kidney
disease, lung disease or upper airway disease and anti-Pr3
serum antibodies are shown to be more resistant to initial
treatment [95]. In these cases, the use of alternative agents
must be considered. Recent investigation has focused on
TNF-α inhibitors, B-cell depletion agents, mycophenolate
mofetil, leflunomide and antithymocyte globulin [102-113]. As
indicated in Table 3, new agents are shown to be effective in
certain cases but are followed by high relapse and
complication rates. Most data are preliminary and further
studies are needed for definite conclusions.
Goodpasture’s syndrome
Immunosuppressive treatment should also be urgently
initiated in the case of Goodpasture’s syndrome. Daily
plasma exchange should be started; if tests for anti-GBM
antibodies are found to be negative, plasmapheresis is then
discontinued. A mean of 14 courses of treatment is usually
needed until the anti-GBM antibody titre is normalized.
Prompt and aggressive plasmapheresis for ANCA-positive,
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of renal recovery [11,114].
Systemic lupus erythematosus
DAH due to systemic lupus erythematosus carries a grave
prognosis, and lupus nephritis needs immediate immuno-
suppressive treatment with cyclophosphamide to prevent
end-stage renal disease [115]. To avoid the severe side
effects of the treatment of systemic lupus erythematosus,
including bone marrow suppression, haemorrhagic cystitis,
opportunistic infections, malignant diseases and premature
gonadal failure, new agents such as mycophenolate mofetil
and rituximab are under investigation. Both drugs have led to
effective disease remission with low toxicity but with a high
relapse rate [116,117].
Acute catastrophic antiphospholipid syndrome
In pulmonary–renal syndrome related to acute catastrophic
APS, the mainstay of therapy is anticoagulation [59].
Thrombotic thrombocytopenic purpura
In cases of pulmonary–renal syndrome and thrombotic
thrombocytopenic purpura, mortality exceeded 90% before
the application of plasmapheresis. Today’s response to
treatment with plasmapheresis reaches 80%. While waiting
for plasmapheresis treatment, plasma transfusions are
indicated to make up for the inadequate von Willebrand
factor cleavage protein [67].
Despite rigorous treatment, almost 66% of patients with
small-vessel vasculitis and pulmonary–renal syndrome will
need renal transplantation within less than 4 years of initial
presentation. The ICU physician will have to care for patients
with end-stage renal disease due to pulmonary–renal syn-
drome because of an increased rate of fluid and electrolyte
abnormalities, cardiovascular disease, haematological and
neurological abnormalities, and bacterial infections. In the
post-transplant period, the ICU admission rates for these
patients are high and their prognosis remains poor [118].
Conclusions
Pulmonary renal syndrome in the ICU is a life-threatening
entity with an acute onset and with a fulminant course if left
untreated. Appropriate management of such patients
includes early and accurate diagnosis, exclusion of infection,
close monitoring and specialized immunosuppressive treat-
ment coupled with plasma exchange in certain cases. Newer
immunomodulatory agents could confer life-saving options for
refractory disease in the future. Renal transplantation remains
the only alternative for patients with pulmonary–renal
syndrome who develop end-stage renal disease.
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